4137 Commerce Circle, Idaho Falls, ID 83401, Phone: 208-524-5300, www.intisoid.com
Good For The Community. Good For The Environment.
Symbol: OTC Bulletin Board (INIS)
- International Isotopes Inc. (“INIS” or the “Company”), headquartered in Idaho Falls, Idaho, was formed as a Texas corporation in 1995.
- The Company’s core business consists of six reportable segments which include; Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, Radiological Services, and Transportation.
- Beginning in 2004, INIS started a major undertaking to construct the first commercial uranium de-conversion and fluorine extraction facility in the U.S.
- INIS believes this new commercial facility will provide an excellent commercial opportunity because:
(i) There is a major shift underway from foreign to domestic uranium enrichment that will result in several new commercial enrichment facilities in the U.S. with no commercial treatment options for the vast amount of by-products of enrichment.
(ii) INIS holds patents that give it exclusive rights for the Fluorine Extraction Process (FEP), a process that produces high value, high purity fluoride gasses in conjunction with uranium de-conversion.
Uranium De-Conversion Plant Overview
- INIS has developed a unique process to convert depleted uranium tails (by-product produced from the enrichment of uranium) to ultra high purity, high value industrial fluoride products.
- The Company has its first de-conversion Service Agreement already in place with URENCO USA -the leader in U.S. commercial enrichment.
- No commercial competition globally and high barriers to entry.
- Fluoride products are a key raw material for microelectronics, fiber optic cable, thin film photovoltaics (solar cells) and a host of other manufacturing processes.
- Provides uranium enrichment producers an alternative for managing or reducing their inventories of depleted uranium.
- Facility will be located on 640-acre site in New Mexico and cost an estimated 125 million for the phase 1 project.
- Construction expected to begin as early as mid 2012.
- Approximately 150 employees will be required to operate facility.
- The anticipated volumes of depleted uranium from enrichment are growing and will provide future opportunities for phased expansion of the facility.
New Commercial Uranium Enrichment in the U.S.
Estimated Annual U.S. Production of DUF6 (mm lbs)
Key Investment Highlights
- Innovative and patented solution: INIS’ Fluorine Products Division (FPD) has spent years developing a patented, commercially viable Fluorine Extraction Process (FEP) that enables the company to use large quantities of depleted UF6 to produce ultra high purity, high value fluoride gases, such as Silicon Tetrafluoride. The INIS’ solution fills a “void” in the nuclear fuel cycle.
- Proven fluorine extraction process for producing high-demand specialty gases: In 2006, INIS built and has successfully operated an 8,000 square foot pilot plant in Idaho Falls that has produced germanium tetrafluoride based on its patents. The pilot plant, and prior demonstration operations, have proven that large scale commercial production of fluoride gases is both technologically viable and potentially highly profitable. The associated technologies for depleted uranium deconversion have also been demonstrated on a large commercial scale. The Company’s newly approved FEP process patent will provide global IP protection or licensing opportunities.
- Multiple revenue streams increase financial return and increase the commercial viability of the opportunity: INIS will complete off-take agreements with U.S.-based enriched uranium producers to provide de-conversion services. The Company has already signed its first contract for de-conversion services with URENCO USA.
- Green Technology: The INIS process will recycle what would otherwise become a waste product by effectively recovering the valuable fluorine and producing products important to technology and alternative energy. In addition, the INIS processes will produce these products using just a fraction of the energy typically required using conventional manufacturing methods.
- Experienced team and proven track record: INIS has many years of experience manufacturing nuclear medicine products and handling radioactive materials and has been licensed by the NRC for over a decade to handle nuclear products.
- Rapidly expanding U.S. and foreign enrichment will provide significant growth opportunities: World-wide, 250 million pounds of depleted UF6 are being produced each year. The initial plant will be a modular design that will facilitate future phased expansion of the facility and its processing capability. This expansion capability, coupled with the regulatory requirements for this type of a facility, will present both excellent growth opportunities and significant barriers to competition.
- Licensing for the facility is already underway and proceeding on schedule: The Company submitted its license application to the US Nuclear Regulatory Commission (NRC) in December 2009 and expects receipt of the license around mid 2012.